Somewhat Positive News Coverage Somewhat Unlikely to Affect Endologix (ELGX) Stock Price

News headlines about Endologix (NASDAQ:ELGX) have trended somewhat positive on Thursday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endologix earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 47.1988281459119 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Several research firms have recently issued reports on ELGX. Zacks Investment Research upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Monday, March 19th. ValuEngine lowered shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Oppenheimer set a $5.00 price objective on shares of Endologix and gave the stock a “hold” rating in a report on Thursday, February 22nd. BidaskClub upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. Finally, JPMorgan Chase lowered shares of Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $5.41.

NASDAQ ELGX traded up $0.16 during mid-day trading on Thursday, reaching $4.35. The stock had a trading volume of 385,762 shares, compared to its average volume of 662,938. The company has a quick ratio of 1.62, a current ratio of 2.36 and a debt-to-equity ratio of 2.77. Endologix has a 1 year low of $3.75 and a 1 year high of $7.66. The firm has a market cap of $340.76, a P/E ratio of -9.06 and a beta of 0.32.

Endologix (NASDAQ:ELGX) last posted its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. Endologix had a negative net margin of 36.65% and a negative return on equity of 44.91%. The business had revenue of $44.00 million during the quarter, compared to the consensus estimate of $44.91 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. The firm’s revenue was down 7.3% on a year-over-year basis. equities analysts expect that Endologix will post -0.73 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/05/endologix-elgx-getting-somewhat-favorable-news-coverage-report-shows/2027887.html.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.